Andrea Rubbert-Roth

Summary

Affiliation: University of Cologne
Country: Germany

Publications

  1. ncbi [Vaccination in adult rheumatology]
    A Rubbert-Roth
    Medizinische Klinik I, Universitätsklinik Köln, Joseph Stelzmann Strasse 9, 50924 Köln
    Z Rheumatol 66:102-4, 106-10. 2007
  2. ncbi Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review
    Andrea Rubbert-Roth
    Department of Internal Medicine, University of Cologne, Josef Stelzmann Strasse, 50924 Cologne, Germany
    Arthritis Res Ther 11:S1. 2009
  3. ncbi TRU-015, a fusion protein derived from an anti-CD20 antibody, for the treatment of rheumatoid arthritis
    Andrea Rubbert-Roth
    University of Cologne, Medical Clinic I, Germany
    Curr Opin Mol Ther 12:115-23. 2010
  4. ncbi [Orphan diseases in rheumatology. Exemplified by polyarteritis nodosa]
    A Rubbert-Roth
    Klinik I fur Innere Medizin, Uniklinik Köln, Koln, Deutschland
    Z Rheumatol 71:119-21. 2012
  5. ncbi Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)
    Hans Peter Tony
    Medizinische Klinik und Poliklinik II, Universitatsklinikum Wurzburg, Klinikstr 6 8, 97070 Wurzburg, Germany
    Arthritis Res Ther 13:R75. 2011
  6. ncbi [Anti-B-cell strategies in vasculitides and collagenoses]
    A Rubbert-Roth
    Medizinische Klinik I der Universitat zu Koln, Koln
    Z Rheumatol 68:390-6. 2009
  7. ncbi [Rheumatoid arthritis: early aggressive therapy including biologicals -- pro]
    A Rubbert-Roth

    Dtsch Med Wochenschr 130:1900. 2005
  8. ncbi [§ 116b SGB V (social insurance code, book five) for rheumatology patients. An empirical assessment on the basis of administrative data]
    T Rath
    Institut fur Gesundheitsokonomie und Klinische Epidemiologie, Universitätsklinik Köln, Gleueler Str 176 178, 50935, Koln
    Z Rheumatol 70:56-63. 2011
  9. ncbi Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders
    H F Petereit
    Department of Neurology, Heilig Geist Krankenhaus, Koln, Germany
    Mult Scler 15:189-92. 2009
  10. ncbi [Interleukin-1 receptor antagonist anakinra (Kineret) for treatment of rheumatic arthritis]
    Andrea Rubbert-Roth
    Med Klinik I der Universität zu Köln, Joseph Stelzmann Str 9, 50924 Köln, Germany
    Z Rheumatol 62:367-77. 2003

Collaborators

Detail Information

Publications12

  1. ncbi [Vaccination in adult rheumatology]
    A Rubbert-Roth
    Medizinische Klinik I, Universitätsklinik Köln, Joseph Stelzmann Strasse 9, 50924 Köln
    Z Rheumatol 66:102-4, 106-10. 2007
    ..Vaccination strategies in cases in which the use of rituximab and abatacept is planned are currently unclear...
  2. ncbi Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review
    Andrea Rubbert-Roth
    Department of Internal Medicine, University of Cologne, Josef Stelzmann Strasse, 50924 Cologne, Germany
    Arthritis Res Ther 11:S1. 2009
    ..This review outlines the current evidence in support of the available treatment strategies in patients with an inadequate response or intolerance to an initial TNF inhibitor...
  3. ncbi TRU-015, a fusion protein derived from an anti-CD20 antibody, for the treatment of rheumatoid arthritis
    Andrea Rubbert-Roth
    University of Cologne, Medical Clinic I, Germany
    Curr Opin Mol Ther 12:115-23. 2010
    ..In addition, this agent also may be useful to the treatment of B-cell neoplasms and autoimmune diseases...
  4. ncbi [Orphan diseases in rheumatology. Exemplified by polyarteritis nodosa]
    A Rubbert-Roth
    Klinik I fur Innere Medizin, Uniklinik Köln, Koln, Deutschland
    Z Rheumatol 71:119-21. 2012
    ..With this in mind it is much more realistic to treat such patients in specialized centers or at least to allow an evidence-based medical treatment in, for example network associations, using the targeted documentation of patients...
  5. ncbi Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)
    Hans Peter Tony
    Medizinische Klinik und Poliklinik II, Universitatsklinikum Wurzburg, Klinikstr 6 8, 97070 Wurzburg, Germany
    Arthritis Res Ther 13:R75. 2011
    ....
  6. ncbi [Anti-B-cell strategies in vasculitides and collagenoses]
    A Rubbert-Roth
    Medizinische Klinik I der Universitat zu Koln, Koln
    Z Rheumatol 68:390-6. 2009
    ..Data on only a few indications from randomized, double-blind studies are available; however, even these results should be evaluated critically...
  7. ncbi [Rheumatoid arthritis: early aggressive therapy including biologicals -- pro]
    A Rubbert-Roth

    Dtsch Med Wochenschr 130:1900. 2005
  8. ncbi [§ 116b SGB V (social insurance code, book five) for rheumatology patients. An empirical assessment on the basis of administrative data]
    T Rath
    Institut fur Gesundheitsokonomie und Klinische Epidemiologie, Universitätsklinik Köln, Gleueler Str 176 178, 50935, Koln
    Z Rheumatol 70:56-63. 2011
    ..This study investigates what proportion of hitherto inpatient rheumatologic care could potentially be given on an outpatient basis...
  9. ncbi Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders
    H F Petereit
    Department of Neurology, Heilig Geist Krankenhaus, Koln, Germany
    Mult Scler 15:189-92. 2009
    ....
  10. ncbi [Interleukin-1 receptor antagonist anakinra (Kineret) for treatment of rheumatic arthritis]
    Andrea Rubbert-Roth
    Med Klinik I der Universität zu Köln, Joseph Stelzmann Str 9, 50924 Köln, Germany
    Z Rheumatol 62:367-77. 2003
    ..Studies are currently assessing the use of anakinra for treatment of other rheumatic diseases like psoriatic arthritis, juvenile arthritis or spondylarthropathy...
  11. ncbi [New biological therapeutic options for the treatment of RE: inhibition of costimulatory molecules and blockade of Interleukin-6-interaction]
    A Perniok
    Klinikum der Universität zu Köln, Klinik und Poliklinik fur Innere Medizin II, Joseph Stelzmann Strasse 9, 50931 Koln, Germany
    Z Rheumatol 62:433-8. 2003
    ..Encouraged by data on these two agents there is substancial hope for a broadened therapeutic armentarium of biological agents in refractory rheumatoid arthritis...
  12. ncbi Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
    Josef S Smolen
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Lancet 371:987-97. 2008
    ..Our aim was to assess the therapeutic effects of blocking interleukin 6 by inhibition of the interleukin-6 receptor with tocilizumab in patients with rheumatoid arthritis...